| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 69
| Issue : 1 | Page : 115--118 |
Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease
Li-Xia Qin1, Jie-Qiong Tan2, Hai-Nan Zhang1, Jian-Guang Tang1, Bo Jiang1, Xiang-Min Shen1, Ji-Feng Guo3, Li-Ming Tan1, Beisha Tang3, Chun-Yu Wang1
1 Department of Neurology, The Second Xiangya Hospital, Changsha, China
2 State Key Laboratory of Medical Genetics, Changsha, China
3 State Key Laboratory of Medical Genetics; Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
Correspondence Address:
Chun-Yu Wang
Department of Neurology, The Second Xiangya Hospital, Central South University, 139 # The People Road, Changsha - 410 011
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0028-3886.310102
Context: A host of microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, microRNA changes are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, and depression. Compared with other body fluids, CSF can reflect the brain pathological processes more accurately.
Aims: To understand whether microRNA expression may be misregulated in patients with PD, and further discover potential diagnostic biomarkers and promising therapeutic targets for PD.
Materials and Methods: Here, through real-time reverse-transcription polymerase chain reaction (RT-PCR), we compared CSF microRNA from 15 PD patients, 11 AD patients, and 16 controls with other neurologic disorders, such as encephalitis and Guillain–Barre syndrome.
Results: Finally, we identified hsa-miR-626 changes in the CSF of PD patients. The mean expression level of hsa-miR-626 was significantly reduced in the CSF of PD patients compared with AD patients and controls.
Conclusions: Our approach provides a preliminary research for identifying biomarkers in the CSF that could be used for the detection, diagnosis, and monitoring of PD.
[FULL TEXT] [PDF]*
|
